Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nepal Healthcare Times.
Press releases published on August 19, 2025
Scientists Discuss the Recent CancerVax Breakthrough
Lehi, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, August 19, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced the release of a video …
Basilea mit starkem Halbjahresergebnis 2025 auf Kurs
Cresemba- und Zevtera-basierte Umsätze steigen um 24 % auf CHF 90.5 Mio. Gesamtumsatz steigt signifikant um 36 % auf CHF 104.0 Mio. Betriebsgewinn springt um 160 % auf CHF 24.0 Mio. Operativer Cashflow erhöht sich um 29 % auf CHF 23.1 Mio. Guidance für das …
Basilea on track with strong 2025 half-year results
Cresemba® and Zevtera®-related revenues rise by 24% to CHF 90.5 million Total revenue grows significantly by 36% to CHF 104.0 million Operating profit surges by 160% to CHF 24.0 million Operating cash flow increases by 29% to CHF 23.1 million Full-year …
Santhera schließt Vereinbarung mit Uniphar über den Vertrieb von AGAMREE® (Vamorolon) in fünf Ländern des Golf-Kooperationsrats (GCC)
Pratteln, Schweiz, 19. August 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer exklusiven Vereinbarung mit Uniphar über den Vertrieb von AGAMREE® (Vamorolon) in den Vereinigten Arabischen Emiraten, Saudi-Arabien, Kuwait, Oman und …
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Pratteln, Switzerland, 19 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, …
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood- …